ENYO Pharma is a clinical stage company with an innovative approach inspired by viruses. Our biotech mimics virus strategy to modulate host cellular functions with multiple applications. We develop new drug candidates in multiple indications such as infectious diseases (e.g. HBV), metabolic diseases (e.g. NASH) and oncology. Our main candidate Vonafexor (EYP001, FXR agonist) is in Phase 2 for both chronic hepatitis B and Non-Alcoholic Steato-Hepatitis. Our second candidate, EYP002, is currently in preclinical studies. Initially developed against influenza virus, it has a mitochondrial cellular target which leads ENYO Pharma to explore new indications such as oncology or metabolic diseases. Thanks to the MIMESIS project, funded by European Union’s Horizon 2020 Research and Innovation Program, ENYO Pharma has a portfolio of early molecules for various indications (RSV, Immunogenic Cell Death, Zika virus, rhinovirus, influenza virus and Mycobacterium tuberculosis) ENYO Pharma is also a member of the CARE consortium (Corona Accelerated R&D in Europe), the largest European research initiative addressing the drug discovery challenges of COVID-19, funded by IMI 2 JU. ENYO Pharma is currently based in Lyon, France and in Melbourne, Australia.